ProShares Ultra NASDAQ Biotechnology
27 hedge funds and large institutions have $16.2M invested in ProShares Ultra NASDAQ Biotechnology in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 16 closing their positions.
34% more call options, than puts
Call options by funds: $6.66M | Put options by funds: $4.96M
1.42% less ownership
Funds ownership: 8.7% → 7.29% (-1.4%)
34% less funds holding
Funds holding: 41 → 27 (-14)
54% less capital invested
Capital invested by funds: $34.8M → $16.2M (-$18.6M)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.45M |
| 2 |
VF
Virtu Financial
New York
|
+$1.89M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$825K |
| 4 |
SBIA
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
|
+$261K |
| 5 |
BRC
Bell Rock Capital
Rehoboth Beach,
Delaware
|
+$210K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Howard Capital Management
Roswell,
Georgia
|
-$6.93M |
| 2 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$3M |
| 3 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$997K |
| 4 |
SAM
Stansberry Asset Management
Westlake,
Texas
|
-$675K |
| 5 |
Jane Street
New York
|
-$648K |
BIB Hedge Fund Activity: Q4 2018 in Review
27 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2018, worth a combined $16.2M — down 54% from $34.8M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of BIB and 3 opened new positions — a net loss of 13 holders — while 9 trimmed existing stakes and 4 added.
The largest buyer was Susquehanna International Group, adding an estimated $2.45M. The largest seller was Howard Capital Management, exiting entirely with an estimated $6.93M sold.
- 27 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2018, down from 41 in Q3 2018.
- Funds reported $16.2M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2018, down 54% quarter-over-quarter.
- 3 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2018 and 16 closed out, a net change of -13 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2018 was Susquehanna International Group, an estimated $2.45M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2018 was Howard Capital Management, an estimated $6.93M sold.
Based on aggregated 13F filings for Q4 2018.